Burning Rock Biotech Ltd is a leading provider of next-generation sequencing-based cancer therapy selection and early detection products and services in China. The company integrates proprietary technologies with a commercial infrastructure to deliver genomic testing solutions for oncology patients. It operates primarily through central and in-hospital laboratory models to support hospitals and physicians across the country.
Burning Rock Biotech Ltd generates revenue through the sale of its next-generation sequencing-based cancer therapy selection tests, minimal residual disease detection products, and early cancer detection assays. Revenue is derived from both its central laboratory model, where it processes samples from partner hospitals and issues reports, and its in-hospital model, where it provides turnkey laboratory solutions and sells reagent kits on a recurring basis. The company serves hospitals, physicians, and patients across China, with additional revenue streams from collaborations with pharmaceutical companies for clinical trial support and companion diagnostics development.
The company operates through the following segments: Central Laboratory Model and In-Hospital Model.
- Central Laboratory Model focuses on processing tissue and liquid biopsy samples delivered by hospitals across China to its certified central laboratory in Guangzhou, where it conducts testing and issues reports typically within six days for oncology products, supporting collaborations with pharmaceutical companies and serving over 7,000 physicians from 845 hospitals.
- In-Hospital Model involves partnering with hospitals to establish in-house laboratories by providing turnkey solutions including equipment installation, workflow customization, training, and ongoing support, followed by recurring sales of reagent kits, with 92 hospitals partnered across 43 cities as of December 31, 2024.
Burning Rock Biotech Ltd holds a leading position in China’s next-generation sequencing-based cancer therapy selection market, particularly in lung cancer testing, and competes with domestic players such as AmoyDx, BGI, and Geneseeq through its proprietary technologies, high sensitivity and specificity, CLIA and CAP accreditation, and strong relationships with pharmaceutical companies and key opinion leaders.
The company serves hospitals, physicians, and patients across China, with specific named collaborators including AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA for clinical trials and companion diagnostics development.